5 completed, 1 terminated. 4 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow edasalonexent: new trials by email Literature Review of edasalonexent trials Research Report on edasalonexent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects Edasalonexent 2000 mg TID, Midazolam 2 MG/ML, Deflazacort 36Mg Tab - Healthy | Phase 1 | Completed | Catabasis Pharmaceuticals | 26 | 2020-08-08 | 2021-01-28 |
| An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy Edasalonexent - Duchenne Muscular Dystrophy | Phase 3 | Terminated | Catabasis Pharmaceuticals | 130 | 2019-03-14 | 2020-11-23 |
| Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy Edasalonexent, Placebo - Muscular Dystrophy, Duchenne | Phase 3 | Completed | Catabasis Pharmaceuticals | 131 | 2018-10-02 | 2022-06-21 |
| Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy Edasalonexent, Placebo - Muscular Dystrophy, Duchenne | Phase 1 / Phase 2 | Completed | Catabasis Pharmaceuticals | 31 | 2016-04-01 | 2022-09-23 |
| A Study of CAT-1004 Biomarkers in Healthy Subjects CAT-1004, Salsalate + DHA, Placebo - Assessment of Mechanistic Blood Biomarkers in Healthy Humans | Phase 1 | Completed | Catabasis Pharmaceuticals | 9 | 2012-08-01 | 2012-10-30 |
| Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers Drug, Placebo - Healthy | Phase 1 | Completed | Catabasis Pharmaceuticals | 52 | 2011-09-01 | 2012-02-06 |
Muscular Dystrophies (3) · Muscular Dystrophy, Duchenne (3) · Musculoskeletal Diseases (3) · Neuromuscular Diseases (3) · Nervous System Diseases (1)
United States (6) · Australia (2) · Canada (2) · Germany (2) · Sweden (2) · United Kingdom (2) · Ireland (1) · Israel (1)
Joanne Donovan, MD, PhD (2) · Joanne M Donovan, Chief Medical Officer, MD, PhD (1) · Joanne M Donovan, MD, PhD (1) · Scott Rasmussen, MD (1)